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SUMMARY  
We report on a 43-year-old patient presenting with a two-week history of painless ascending 
sensory disturbances suspected to suffer from acute inflammatory polyneuropathy. On clinical 
examination, deep tendon reflexes were preserved and muscle strength was 5/5 everywhere. 
Gait was ataxic with positive Romberg test. Lumbar puncture was normal and 
electroneurography demonstrated demyelination. With spinal-cord involvement centred on the 
posterior tracts on MRI, differential diagnosis focused on cobalamin-deficiency. Initial 
laboratory work-up showed nearly normal holotranscobalamin (43pmol/l, normal>50) not 
suggesting vitamin B12-deficiency. Surprisingly, further testing including methylmalonic acid 
(3732nmol/l, normal<271) and homocysteine (48.5umol/l, normal<10) proofed an 
impairment of vitamin-B12-dependent metabolisms leading to the diagnosis of subacute 
combined degeneration. Only after repeated history taking, the patient remembered having 
taken tablets containing cobalamin for three days before hospitalization. In case of B12-
deficiency, holotranscobalamin can rapidly normalize during supplementation, whereas 
methylmalonic acid and homocysteine might help to detect B12-deficiency in patients who 
started supplementation recently.   
 
BACKGROUND  
Acute ascending sensory deficits constitute a neurological emergency and require a thorough 
clinical evaluation and diagnostic work-up. The differential diagnosis of this clinical picture is 
broad and some underlying disorders require close monitoring and immediate treatment. This 
is especially true for acute inflammatory demyelinating polyneuropathy as it may rapidly 
progress and lead to respiratory failure and severe autonomic disturbances [1]. This disorder 
needs to be distinguished from other potential causes of ascending sensory deficits including 
toxic and malnutrition-related neuropathies and transverse myelopathy. Polyneuropathy due 
to cobalamin (vitamin-B12) deficiency, which can be attended by spinal cord and brain 
demyelination, is treatable by vitamin B12 substitution and is potentially reversible when 
treated early [2]. 
In the case presented here we lead through the diagnostic work-up for acute ascending 
sensory deficits and discuss potential pitfalls in the laboratory diagnostics of vitamin B12 
deficiency. 
 
CASE PRESENTATION  
A 43-year-old male presented with a two-week history of painless ascending sensory 
disturbances affecting legs and arms. The patient had no cognitive complaints or visual 
disturbances. On initial history taking no toxic exposure or drug intake was reported 
(especially no use of acid-suppressing medication). The patient stated frequent consumption of 
meat products. The patient had no history of gastric surgery. Family history for neurological 
disorders was negative. On clinical examination, impaired touch and pain sensation (reaching 
up to the elbows and knees) was reported, and position sense and vibration sense were 
strongly reduced at the feet. There was also impaired sensation for touch below dermatome 
Th7 bilaterally. Deep tendon reflexes (including the Achilles tendon reflex) were weak but 
symmetric. Babinski sign was negative and muscle tone was normal. Muscle strength was 5/5 
everywhere. Romberg showed increased sway, and gait was broad-based/ataxic. Cranial 
nerves were normal; no cerebellar deficits were noted. Later during hospitalization we learned 
about intramuscular B12-substitution two years before hospitalisation due to vitamin B12 
deficiency without clinical symptoms detected in a routine screening as part of a health check-
up (serum-B12 level May 2012: 120 pmol/l, normal: >180). 
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INVESTIGATIONS  
Lumbar puncture was normal (including normal cell count, glucose, lactate and negative 
syphilis serology) except for slightly elevated total protein (0.56g/l, normal<0.5). 
Electroneurography showed increased distal motor latencies and reduced nerve conduction 
velocities and slightly increased F-wave latencies at the legs (Table 1), while electromyography 
was normal. Noteworthy, except for moderately reduced amplitude of the compound muscle 
action potential of the median nerve, no axonal changes were noted. These findings were 
consistent with sensorimotor demyelinating polyneuropathy of the legs.  
 
Table 1: electroneurographic (ENG) findings (6 days after symptom onset): 
Nerve Motor nerve 
conduction velocity 
(m/s) 
Distal 
motor 
latency 
(ms) 
Temporal 
dispersion 
F-latency 
(ms) 
Sensory nerve 
conduction velocity 
(m/s) 
cMAP (mV) / 
sNAP (µV) 
L median N  distal 50 (n>48) 
proximal 62 (n>48) 
4.1 
(n<4.0) 
none 29.4 
(n<31) 
distal 52 (n>49) 
proximal 51 (n>52) 
3.0 / 20.6 
R median N  distal 46 (n>48) 
proximal 65 (n>48) 
4.2 
(n<4.0) 
none NA distal 56 (n>49) 
proximal 50 (n>52) 
7.7 / 23.0 
L ulnar N NA 3.0 
(n<3.2) 
none 29.0 
(n<32) 
distal 50 (n>41) 
proximal NA 
8.7 / 22.9 
R ulnar N distal 53 (n>44) 
proximal 69 (n>45) 
2.5 
(n<3.2) 
none 29.9 
(n<32) 
distal 48 (n>41) 
proximal 61 (n>46) 
7.9 / 19.6 
L peroneal N distal 38 (n>42) 
proximal 59 (n>41) 
5.8 
(n<4.9) 
none 59.9 
(n<56) 
NA 5.6 (n>2.6 
mV) / NA 
R peroneal N distal 26 (n>42) 
proximal 46 (n>41) 
5.2 
(n<4.9) 
none 66.7 
(n<56) 
NA 4.1 (n>2.6 
mV) / NA 
L tibial N 29 (n>40) 4.8 
(n<5.5) 
none 65.5 
(n<58) 
NA 12.6  (n>5.8 
mV) / NA 
R tibial N 19 (n>40) 5.1 
(n<5.5) 
none 71.1 
(n<58) 
NA 8.7 (n>5.8 
mV) / NA 
L sural N 
(orthodrome, 
needle ENG) 
NA NA NA NA 38 (n>48) NA / 12.3 
R sural N 
(orthodrome, 
needle ENG) 
NA NA NA NA 40 (n>48) NA / 19.5 
Abbreviations: NA =not available 
 
With normal median and ulnar nerve measurements, the upper extremity sensory deficits 
remained unexplained. We therefore obtained spinal cord imaging, demonstrating non-
enhancing T2-hyperintensities (Fig 1AB) on the posterior columns (C2 to C5), which is 
characteristic of subacute combined degeneration. Cerebral MRI showed no abnormalities and 
neuropsychological testing demonstrated no cognitive deficits. Differential diagnosis now 
focused on cobalamin deficiency. However, initial laboratory work-up showed almost normal 
holotranscobalamin (43pmol/l, normal>50) levels not typical for clinically relevant vitamin B12 
deficiency. Surprisingly, further laboratory testing demonstrated strongly increased 
methylmalonic acid (=MMA; 3732nmol/l, normal<271) and plasma total homocysteine 
(48.5umol/l, normal<10) levels proofing an impairment of vitamin B12-dependend 
metabolisms. Folate, zinc and copper levels were normal. These findings supported the 
diagnosis of cobalamin-associated subacute combined degeneration and peripheral 
polyneuropathy. Only after repeated history taking, the patient remembered having taken 
cobalamin-containing tablets for three days before hospitalization. We additionally analysed 
total cobalamin (133ng/l, normal range=180-914) from the initial blood sample, also showing 
only a moderately reduced level. 
During the course of hospitalization, the patient developed shortness of breath and chest pain. 
With underlying pulmonary embolism confirmed by chest CT, he was started on rivaroxaban. 
 
DIFFERENTIAL DIAGNOSIS  
Differential diagnosis was driven by the initial presentation of ascending sensory disturbances 
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and demyelinating neuropathy, while deep tendon reflexes were preserved and lumbar 
puncture was normal except for slightly elevated total protein levels. This combination made 
acute inflammatory demyelinating polyneuropathy unlikely and re-enforced a diagnostic work-
up. In view of myelopathy, ischemia, metabolic-toxic causes and malnutrition/malabsorption 
were considered. With very high MMA and homocysteine levels, cobalamin deficiency became 
the most likely cause despite almost normal holotranscobalamin levels. Low iron serum levels 
supported the hypothesis of malnutrition/malabsorption. The supplementation of cobalamin a 
few days before hospitalisation explains why holotranscobalamin and total cobalamin levels 
were only slightly decreased on admission. 
 
TREATMENT 
Treatment with subcutaneous cyanocobalamin (1000 mcg) given every other day was initiated 
(intramuscular application was contraindicated due to pulmonary embolism treated with 
therapeutic heparin). Folic acid was supplemented as well. 
 
OUTCOME AND FOLLOW-UP 
Under treatment with cyanocobalamin, MMA and homocysteine levels continuously decreased, 
and were normal again after one month (Fig 2). Clinically, the patient reported significant 
improvement of sensory disturbances and gait ataxia. Follow-up MRI after two months showed 
significant regression of the dorsal column hyperintensities (Fig. 1CD). Upper gastrointestinal 
endoscopy revealed several duodenal ulcera, while no helicobacter pylori was found on biopsy, 
and anti-intrinsic factor and anti-parietal cell antibodies were negative. To which extent these 
duodenal ulcera reduced cobalamin absorption remains unclear. The patient is now under oral 
cobalamin and folic acid supplementation and received a proton pump inhibition treatment for 
six weeks. On follow-up examination four months after symptom onset sensory disturbances 
were greatly reduced with slight residual deficits in touch and pain sensation at the feet, while 
vibration and position sense had normalized. 
 
DISCUSSION 
This case highlights possible diagnostic pitfalls in patients presenting with subacute ascending 
sensory disturbances and demyelinating neuropathy. First it shows that history taking and 
laboratory work-up with holotranscobalamin (or total cobalamin) alone can be misleading. 
Second, it underlines the importance of detailed and repeated drug history taking including 
asking for supplementary substances, especially if diagnostic tests are suggestive of a 
malnutrition-related disorder. In this case, holotranscobalamin levels were probably almost 
back to normal due to cobalamin supplementation initiated few days before hospitalization. 
However, strongly elevated blood levels of MMA and homocysteine proofed the ongoing 
metabolic deficiency and the decrease of MMA and homocysteine levels under appropriate 
supplementation with cyanocobalamin further supported this diagnosis (see [3] for a detailed 
review). Thus, this case emphasizes the assessment of metabolites of cobalamin including 
MMA and homocysteine to increase sensitivity for cobalamin deficiency, especially since total 
cobalamin and holotranscobalamin levels may still be normal or borderline normal while 
increased metabolites (MMA, homocysteine) already indicate cobalamin deficiency [4 5]. With 
only 0.1% of a middle-aged control group having MMA concentrations above 750nmol/l [6], a 
positive MMA just by chance seems very unlikely in our patient. Especially, as it was 
accompanied by severe homocysteine elevation in the presence of normal folate levels also 
strongly suggesting vitamin B12 deficiency. Upper gastrointestinal endoscopy belongs to the 
standard diagnostic work-up in patients with cobalamin deficiency to identify those cases with 
autoimmune or helicobacter pylori-associated gastritis and distinguish them from those with 
malnutrition or other causes of gastrointestinal malabsorption such as gluten-induced 
enteropathy, gastric bypass surgery or chronic alcohol ingestion. In our patient, however, the 
isolated duodenal ulcera with negative anti-intrinsic factor antibodies may not be sufficient to 
link cobalamin deficiency with gastrointestinal malabsorption. Also, long term-use of acid-
suppressing medication (proton pump inhibitors and histamine 2 receptor antagonists) needs 
to be considered as an underlying cause of vitamin B12 malabsorption. Gastric acid is essential 
to cleave vitamins from nutritional proteins and intrinsic factor, which is required for 
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absorption of vitamin B12 in the ileum, is produced by the same cells that produce gastric acid 
[7]. 
With regards to the differential diagnosis, a distinction from acute inflammatory demyelinating 
polyneuropathy is essential – especially due the very recent symptom onset (about 2 weeks 
ago). However, both lack of cytoalbuminologic dissociation and preserved deep tendon 
reflexes speak against an inflammatory cause of the polyneuropathy. While the majority of 
cobalamin deficiency associated polyneuropathies is axonal or combined axonal-demyelinating, 
about 10-25% are purely demyelinating [8 9]. This may make distinction from an 
inflammatory cause of the neuropathy more difficult, especially, if symptom onset is very 
recent. Importantly, possible spinal cord involvement has to be addressed if clinical findings 
are not satisfactory explained by peripheral neuropathy. T2-hyperintensive myelopathy on MRI 
being most prominent at the posterior columns accompanied by clinical signs of damage of the 
posterior columns (impaired position-/ vibration-sense, decreased touch) is characteristic of 
subacute combined degeneration [10 11] and must initiate an intense search for cobalamin 
deficiency, while the clinician must be aware of the differential diagnosis including syphilitic 
myelopathy (tabes dorsalis) and copper deficiency (if cobalamin metabolites are normal) [12]. 
To our knowledge no similar cases with almost normal holotranscobalamin levels but severe 
MMA increases due to short-term supplementation have been published in the literature.  
The pulmonary embolism found in our patient is possibly linked to the cobalamin deficiency 
also as high homocysteine levels were associated with an increased risk for venous thrombosis 
[13]. 
 
LEARNING POINTS/TAKE HOME MESSAGES 
 
• While acute / subacute ascending sensory deficits must initiate an urgent diagnostic 
work-up for acute inflammatory demyelinating polyneuropathy, normal protein levels 
and cell count on spinal tab, preserved deep tendon reflexes and electroneurographic 
measurements falling short of explaining all sensory deficits sufficiently make this 
diagnosis unlikely, shifting the focus on metabolic-toxic and malnutrition-related 
neuropathies that can have combined spinal and peripheral nerve involvement. 
• Laboratory work-up for the evaluation of possible cobalamin deficiency should include 
holotranscobalamin, homocysteine and MMA, since a single parameter – 
holotranscobalamin in this case – may be almost normal despite severe deficiency as 
indicated by very high MMA serum and homocysteine levels. 
• Drug history, especially long-term use of acid-suppressing medication, is essential for 
evaluation of vitamin B12-deficiency. We strongly recommend routinely evaluating for 
the intake of supplementary substances including vitamins as well.  
• Prompt cobalamin supplementation and regular monitoring of cobalamin metabolites 
under supplementation are essential, as cobalamin-induced (neurological) deficits are 
potentially reversible if treated early.  
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The patient was not involved in a clinical trial 
 
FIGURE/VIDEO CAPTIONS 
 
Fig 1: Magnetic resonance imaging of the spinal cord before (panels A, B) and two months 
after (panels C, D) initiating cobalamin supplementation. T2-weighted axial (panels A, C) and 
sagittal (panels B, D) cuts are presented, demonstrating marked T2-hyperintensity along the 
posterior columns of the cervical spinal cord (as indicated by the black and white arrows) in 
axial and sagittal sections, referred to as subacute combined degeneration. On follow-up, 
these changes were markedly reduced (panel C) or have even disappeared (panel D). 
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Fig 2: Methylmalonic acid (black circles) and holotranscobalamin (black squares) levels 
before and during the first month of supplementation with cyanocobalamin relative to cutoff 
values for MMA (normal range <271 nmol/l) and cyanocobalamin (normal range >50 
pmol/l). 
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